PF810 ABO INCOMPATIBLE KIDNEY TRANSPLANTATION – ONE CENTRE EXPERIENCE

• Published in: HemaSphere 2019-06, Vol.3 (S1), p.357-358
• Main Authors: Sampaio, M., Antunes, M. Bini, Malheiro, J., Dias, L., Martins, L.S., Pedroso, S., Almeida, M., Henriques, A. Castro, Tafulo, S., Oliveira, R., Vasconcelos, F., Amil, M.
• Format: Article
• Language: English
• ISSN: 2572-9241; 2572-9241
• DOI: 10.1097/01.HS9.0000561520.74836.6e

Background: Donor living kidney transplantation (KT) is an available optionfor end‐stage renal disease, improving survival and quality of life when compared with other treatments. ABO incompatibility was considered an important barrier for long but, with the increasing organ shortage and due to improvement of immunosuppression protocols, ABO‐incompatible (ABOi) KT has achieved remarkable success in the last decades, with graft survivals and patient overall survivals comparable to compatible transplantations. Consensually, initial goal is to lower patient ABO antibodies titter to ≤1:16 before transplantation, ≤1:8 during the first week and ≤1:16 during the second week after surgery. Thereafter, even a rebound of ABO antibodies does not appear to harm the graft due to accommodation phenomenon. Current strategies for desensitization include B‐cell‐depleting therapies and intensified immunosuppression as well as plasmapheresis to remove ABO antibodies. Aims: Retrospective evaluation of donor/recipient pairs proposed for ABOi Kidney transplantation between 2015 and 2018. Methods: Donor‐patient pairs were proposed by the Kidney Transplantation Centre. Patients were evaluated for ABO/Rh group, relationship with donor, diagnosis, pre‐KT isoagglutinin anti‐A and anti‐B (IgG and IgM), pre‐KT donor specific HLA antibodies, post‐KT isoagglutinin titter (daily up to D14, at D30, and at sixth month after KT), number of plasmapheresis performed (target: IgG isoagglutinin